Advertisement

 

doctorslounge.com

 
Powered by
Careerbuilder

 

                    Home  |  Forums  |  Humor  |  Advertising  |  Contact
   Ask a Doctor

   News via RSS

   Newsletter

   Home

   News

   Conferences

   CME

   Forum Archives

   Diseases

   Symptoms

   Labs

   Procedures

   Drugs

   Links

advertisement.gif (61x7 -- 0 bytes)

   Specialties

   Cardiology

   Dermatology

   Endocrinology

   Fertility

   Gastroenterology

   Gynecology

   Hematology

   Infections

   Nephrology

   Neurology

   Oncology

   Orthopedics

   Pediatrics

   Pharmacy

   Primary Care

   Psychiatry

   Pulmonology

   Rheumatology

   Surgery

   Urology

   Other Sections

   Membership

   Research Tools

   Medical Tutorials

   Medical Software

     
 
 

 Headlines:

 
 
 
Last Updated: Jun 12, 2009 - 3:53:09 PM

Blood brain barrier breached by new therapeutic strategy
   
Nature
Jun 18, 2007 - 11:56:58 PM
Email this article
 Printer friendly page

A major obstacle in the treatment of infections and other diseases of the brain is the blood-brain barrier, which prevents systemically delivered therapeutic drugs from reaching the brain.

Grantees of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, have now shown that a short protein (peptide) from the rabies virus can carry a strip of therapeutic material into the brain via intravenous administration. Once delivered to the nerve cells of the brain, the strip, called a small interfering RNA (siRNA), was shown to protect mice from infection caused by the Japanese encephalitis virus (JEV).

Manjunath N. Swamy, M.D., of the CBR Institute for Biomedical Research and Harvard Medical School in Boston, and his colleagues used JEV to infect the brains of mice. They then injected the antiviral siRNA bound to the rabies peptide through the tail veins in one group of mice, while other mice served as control groups. All the mice in the control groups died from JEV infection; in contrast, 80 percent of the mice that got the antiviral siRNA linked to the rabies peptide survived. These experiments demonstrate how the rabies peptide can be used to deliver antiviral siRNA across the blood-brain barrier and into nerve cells in the brain. Once inside brain nerve cells, the antiviral siRNA can silence key viral genes to control the infection. Furthermore, repeated administration of the RNA interference therapy did not trigger inflammation or antibodies to the peptide.

Currently, doctors use various methods to deliver therapeutic drugs directly into the brain. These methods involve invasive procedures that result in only localized delivery around the site of injection. The new research provides a safe and non-invasive method for delivering therapeutic molecules across the blood-brain barrier. It has the potential to be applied to the treatment of a variety of brain infections and diseases. The researchers are now trying to improve the efficacy of this delivery system and to make a stable form of siRNA that might yield even better results.

###

Article: “Transvascular delivery of small interfering RNA to the central nervous system,” by N Manjunath et al. Nature DOI: 10.1038/nature05901 (2007)


 
Top of Page

Email this article
Printer friendly page

advertisement.gif (61x7 -- 0 bytes)
 

Are you a doctor or a nurse?

Do you want to join the Doctors Lounge online medical community?

Participate in editorial activities (publish, peer review, edit) and give a helping hand to the largest online community of patients.

Click on the link below to see the requirements:

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 



We subscribe to the HONcode principles of the HON Foundation. Click to verify.
We subscribe to the HONcode principles. Verify here

Privacy Statement | Terms & Conditions | Editorial Board | About us
Copyright © 2001-2007 The Doctors Lounge. All rights reserved.